Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 1
1987 1
1988 1
1989 1
1992 2
1993 3
1994 1
1995 6
1996 2
1997 4
1998 1
1999 2
2000 2
2001 5
2002 2
2003 2
2005 4
2006 1
2008 2
2009 4
2010 2
2011 5
2012 4
2013 6
2014 11
2015 14
2016 5
2017 18
2018 13
2019 8
2020 12
2021 17
2022 10
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

156 results
Results by year
Filters applied: . Clear all
Page 1
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V. Cruz C, et al. Among authors: dougherty b. Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099. Ann Oncol. 2018. PMID: 29635390 Free PMC article.
Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer.
Tcyganov EN, Hanabuchi S, Hashimoto A, Campbell D, Kar G, Slidel TW, Cayatte C, Landry A, Pilataxi F, Hayes S, Dougherty B, Hicks KC, Mulgrew K, Tang CA, Hu CA, Guo W, Grivennikov S, Ali MA, Beltra JC, Wherry EJ, Nefedova Y, Gabrilovich DI. Tcyganov EN, et al. Among authors: dougherty b. J Clin Invest. 2021 Aug 16;131(16):e145971. doi: 10.1172/JCI145971. J Clin Invest. 2021. PMID: 34228641 Free PMC article.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC. Schmid P, et al. Among authors: dougherty b. J Clin Oncol. 2020 Feb 10;38(5):423-433. doi: 10.1200/JCO.19.00368. Epub 2019 Dec 16. J Clin Oncol. 2020. PMID: 31841354 Free article. Clinical Trial.
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes A, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodríguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow S, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan E, Lord CJ, Cruz C, Balmaña J, O'Connor MJ. Serra V, et al. Among authors: dougherty b. Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568. Clin Cancer Res. 2022. PMID: 35921524 Free PMC article.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Hodgson DR, et al. Among authors: dougherty ba. Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24. Br J Cancer. 2018. PMID: 30353044 Free PMC article. Clinical Trial.
Whole-genome random sequencing and assembly of Haemophilus influenzae Rd.
Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al. Fleischmann RD, et al. Among authors: dougherty ba. Science. 1995 Jul 28;269(5223):496-512. doi: 10.1126/science.7542800. Science. 1995. PMID: 7542800
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC. Carr TH, et al. Among authors: dougherty b. Cancers (Basel). 2021 Nov 20;13(22):5830. doi: 10.3390/cancers13225830. Cancers (Basel). 2021. PMID: 34830984 Free PMC article.
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U. Ledermann J, et al. Among authors: dougherty b. Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31. Lancet Oncol. 2014. PMID: 24882434 Clinical Trial.
156 results